Entries by OptimumLogin

Mission Therapeutics Appoints Dr Anne Phelan as Senior Vice President, Head of Discovery Research

CAMBRIDGE, UK – 20 March 2017 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, announced the appointment of Dr Anne Phelan as Senior Vice President, Head of Discovery Research, effective 20 March 2017. Dr Phelan has spent over 20 years […]

Mission Therapeutics Appoints Colin Goddard as Chairman

Michael Moore Transitions to Deputy Chairman CAMBRIDGE, UK – 5 December 2016 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes (DUBs) to treat cancer, neurodegenerative and other diseases, announces that Dr Colin Goddard has been appointed as non-executive Chairman, effective January 1st 2017. Dr Colin Goddard joined the […]

Mission Therapeutics to Attend and Present at Conferences in October and November 2016

CAMBRIDGE, UK – 13 October 2016 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that the company is scheduled to attend the following events: (1) ELRIG Drug Discovery 2016 13-14 October 2016, ACC, Liverpool, UK The Drug Discovery meeting […]

Dr Michael Koslowski listed in the top 20 translational researchers

CAMBRIDGE, UK – 6 October 2016 – Mission Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, is pleased to announce that its Chief Medical Officer, Dr Michael Koslowski has been listed as one of the 20 top translational researchers of 2015 in Nature Biotechnology. […]

Mission Therapeutics to Attend and Present at Conferences in June and July 2016

CAMBRIDGE, UK – 3 June 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that the company is scheduled to attend the following events: (1) American Society of Clinical Oncology (ASCO) Annual Meeting, 3–7 June 2016, McCormick Place, Chicago, […]

Mission Therapeutics to Attend and Present at Conferences in May 2016

CAMBRIDGE, UK – 4 May 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that the company is scheduled to attend the following events: (1) Mitochondrial Medicine: Developing New Treatments for Mitochondrial Disease conference, 4 – 6 May, Wellcome […]

Mission Therapeutics to Present at Conferences in March – April 2016

CAMBRIDGE, UK – 31 March 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that Anker Lundemose, Chief Executive Officer, Dr Xavier Jacq, VP Scientific Affairs, Dr Paul Wallace, Chief Business Officer and Dr Michael Koslowski, Chief Medical Officer […]

Mission Therapeutics to Present at Conferences in March 2016

 CAMBRIDGE, UK – 1 March 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced that Anker Lundemose, Chief Executive Officer, and Dr Xavier Jacq, VP Scientific Affairs, are scheduled to present at the following events: (1) 6th Ubiquitin Research […]

MISSION Therapeutics Raises £60 million to Progress Development of Novel DUB Inhibitors from Innovative Drug Platform

Woodford Patient Capital Trust joins existing syndicate supporting transition to clinical development  CAMBRIDGE, UK – 2 February 2016 – MISSION Therapeutics, a drug discovery and development company focused on selectively targeting deubiquitylating enzymes to treat cancer, neurodegenerative and other diseases, today announced it has raised £60 million. The financing was jointly led by Imperial Innovations […]